TG-1701-101
11 Nov 2020
TG-1701-101
NCT03671590
Study of TG-1701, an irreversible Bruton’s Tyrosine Kinase inhibitor, in patients with B-cell malignancies
TG Therapeutics Inc.
Cancer Type | Lymphoma |
---|---|
Trial Type | Treatment |
Phase | Phase I |
Age Range | 18 years and older |
Sex | Both |
Tumour Stream | Lymphoma |
Cancer Stage | Locally Recurrent or Locally Advanced |
Anticipated Start Date | 2018-09-10 |
Anticipated End Date | 2020-09-01 |
Hospital | Ashford Cancer Centre Research |
---|---|
Clinical Trial Coordinator | Sue Yeend |
syeend@adelaidecancercentre.com.au | |
Phone | 08 8292 2240 |
Principal Investigator | Dr Stanley Cheung |
Recruitment Status | Recruiting |